OSI Joins Genentech In Eye Disease Market With $935 Mil. Eyetech Purchase
Executive Summary
OSI Pharmaceuticals' existing partnership with Genentech will be unaffected by the firm's acquisition of Eyetech Pharmaceuticals, CEO Colin Goddard assured investors Aug. 22
You may also be interested in...
OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
OSI Takes Wait-And-See Approach To Lucentis Impact On Macugen
An early 2006 launch of Genentech's wet age-related macular degeneration candidate Lucentis could impact sales of OSI/Eyetech's competing therapy, Macugen, by an estimated $75 mil. that year, OSI said
Genentech/OSI Tarceva sNDA
FDA's Oncologic Drugs Advisory Committee will review on Sept. 13 Genentech/OSI's Tarceva sNDA (21-743/S003) for first-line treatment, in combination with gemcitabine (Lilly's Gemzar), of patients with locally advanced, unresectable or metastatic pancreatic cancer. The estimated user fee deadline for the sNDA is Nov. 2. Tarceva (erlotinib) was approved in November 2004 for locally advanced or metastatic non-small cell lung cancer (1"The Pink Sheet" Nov. 29, 2004, p. 4). The meeting will be at the Holiday Inn in Bethesda, Md. at 8 a.m. [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...